Format

Send to

Choose Destination
Cytotherapy. 2010 Sep;12(5):576-8. doi: 10.3109/14653249.2010.507330.

Defining the risks of mesenchymal stromal cell therapy.

Author information

1
Texas A&M Health Science College of Medicine, Institute for Regenerative Medicine at Scott & White, Temple, TX 76502, USA. Prockop@medicine.tamhsc.edu

Abstract

We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

PMID:
20735162
DOI:
10.3109/14653249.2010.507330
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center